Ayanian JZ. Changes in Cancer Staging and Timely Treatment After Medicaid Expansion. JAMA Health Forum. Published online March 11, 2020. doi:10.1001/jamahealthforum.2020.0309
Before the Affordable Care Act (ACA) was enacted in 2010, adults without health insurance were more likely than those with private insurance to be diagnosed with breast cancer or colorectal cancer at an advanced stage.1,2 Two principal motivations for the ACA were to improve health outcomes for those who would otherwise have no insurance and provide greater financial protection from health care expenses for individuals facing serious illnesses. For adults with cancer, expanded insurance coverage could reduce cost-associated barriers to screening and evaluation of new cancer-associated symptoms and promote more timely access to effective treatments, thereby reducing cancer-associated morbidity and mortality.
In 2006, Massachusetts enacted a broad expansion of health insurance via Medicaid coverage and subsidized private insurance for adults with lower incomes.3 This state health reform law became a forerunner of the ACA. Relative to other nearby states, expanded coverage in Massachusetts was associated with improved access to primary care4; greater use of screening tests for colorectal, breast, and cervical cancer4,5; diagnosis of colorectal cancer (but not breast cancer) at an earlier stage6; and lower mortality rates, particularly for conditions amenable to health care.7
A recent study in JAMA Network Open by Takvorian et al8 assessed whether Medicaid expansion under the ACA has been associated with improvements in stage at diagnosis and time to initial treatment for adults aged 40 to 64 years who were diagnosed with breast, colon, or non–small cell lung cancer. In a difference-in-differences analysis of the National Cancer Database that included more than 1500 US hospitals, diagnoses of stage I cancer increased significantly by 0.8 percentage points and stage IV cancers decreased by 0.5 percentage points in 24 states that expanded Medicaid in 2014, relative to other states that did not. However, initiation of treatment within 30 or 90 days for patients newly diagnosed with cancer did not differ significantly between Medicaid expansion and nonexpansion states.
Studies, such as this one,8 that compare cancer outcomes in Medicaid expansion and nonexpansion states may underestimate the outcomes of Medicaid expansion, particularly if adults with all levels of income are included. First, prior studies showed that the largest improvements in cancer screening after Massachusetts expanded insurance coverage in 2006 were concentrated among those with the lowest incomes,4,5 so these changes may be diluted in studies of the whole population. Second, many adults in nonexpansion states with incomes between 100% and 138% of the federal poverty level, who would have qualified for Medicaid in expansion states, received subsidized private insurance through ACA-authorized Marketplace plans at relatively low cost. Third, under the ACA, adults with insurance in all states benefited from the elimination of cost-sharing for effective preventive services, including screening tests for breast, colon, and lung cancer.
The associations of the ACA and Medicaid expansion with cancer screening, diagnosis, treatment, and outcomes are crucial for patients, health care professionals, and policy makers to understand more fully. With 12 more states opting to expand Medicaid since the initial 24 expansion states studied by Takvorian and colleagues,8 opportunities to assess the role of Medicaid expansion in cancer care remain important and timely.
Open Access: This is an open access article distributed under the terms of the CC-BY License.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
John Z. Ayanian, MD, MPP Dr John Ayanian is the inaugural Director of the Institute for Healthcare Policy and Innovation at the University of Michigan, the Alice Hamilton Distinguished University Professor of Medicine and Healthcare Policy, Professor of Health Management...